Tanezumab, identified by the research designation 880266-57-9, represents a targeted antibody solution demonstrating significant application in alleviating chronic osteoarthritis pain. This engineered antibody specifically targets sensory growth element , blocking its function and thereby diminishing discomfort within affected locations. The experimental data surrounding 880266-57-9 highlights its power to provide significant suffering alleviation while potentially limiting the need for opioid analgesics. Further investigation are currently underway to thoroughly evaluate its sustained well-being and effectiveness .
Comprehending Tanezumab's Role in Ache Alleviation: An Body's Defense View
Tanezumab, a novel medicinal approach, offers a unique pathway in persistent pain control. As a engineered antibody, it specifically targets and prevents nerve development factor (NGF), a important molecule engaged in neural discomfort signaling. Unlike standard narcotic medications, tanezumab’s antibody mechanism allows for a greater specific action, possibly reducing the risk of some common side reactions associated with systemic pain relief. However, its protein nature necessitates a thorough consideration of possible body's effects and long-term consequences when administered within a full pain management strategy.
Tanezumab Solution (880266-57-9): Composition, Purity & Uses
The Tanezumab Compound with the identifier 880266-57-9 is a essential component in various research applications, particularly concerning joint pain treatment development. Achieving a high standard of purity is paramount; therefore, rigorous analysis protocols are employed to guarantee its fitness for intended use. Our production method focuses on maximizing cleanliness , employing sophisticated purification techniques to remove impurities . Typical specifications include a >95% purity grade as determined by Chromatography and comprehensive examination for protein integrity. The key functions revolve around its role as a scientific resource for investigating pathways of arthritis progression and developing novel medical solutions.
- Biomedical Investigations
- Drug Development
- Pathway Studies
A Science Of Tanezumab:
Tanezumab, identified by the molecular identifier 880266-57-9, represents a novel therapeutic antibody targeting pain-sensing development factor receptor (NGF). Its mode of function revolves about precisely connecting to NGF, thereby blocking its role and following communication propagation. Scientists have demonstrated that this biologic molecule provides potential for managing persistent discomfort, particularly associated with illnesses like osteoarthritis and peripheral back discomfort. More research are underway to fully define its impact and security data.
Latest Progress in The Investigation: Examining the 880266-57-9 Substance
Ongoing analyses surrounding tanezumab, a promising therapeutic agent, are increasingly directed on defining the role of the identified reagent, the reagent. The identification and detailed evaluation of this molecular entity appears necessary for optimizing tanezumab's efficacy and reducing possible undesirable reactions. Preliminary results suggest that it contributes a significant role in the therapy's mode of delivery. Further studies are needed to fully clarify the reagent’s influence.
Tanezumab Antibody (880266-57-9): Production, Characteristics, and Potential
The production process of tanezumab, an humanized monoclonal antibody (identified by CAS number 880266-57-9), typically involves mammalian cell culture, often utilizing Chinese hamster ovary cells for high yield. Its primary characteristic is its ability to selectively target and degrade cathepsin-K, an enzyme crucial for bone resorption. This binding mechanism results in a significant reduction in osteoclast activity. The molecule exhibits a defined molecular weight and specific amino acid sequence, allowing Tanezumab NGF antibody for detailed characterization through techniques such as mass spectrometry and protein sequencing. Consequently, tanezumab’s potential lies in treating conditions characterized by excessive bone loss, like osteoarthritis and metastatic bone disease, although clinical development has been complex due to adverse event profiles and ongoing evaluation.}